Bolt Biotherapeutics - Asset Resilience Ratio
Bolt Biotherapeutics (BOLT) has an Asset Resilience Ratio of 27.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Bolt Biotherapeutics's Asset Resilience Ratio has changed over time. Check Bolt Biotherapeutics (BOLT) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Bolt Biotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bolt Biotherapeutics stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.80 Million | 27.85% |
| Total Liquid Assets | $15.80 Million | 27.85% |
Asset Resilience Insights
- Very High Liquidity: Bolt Biotherapeutics maintains exceptional liquid asset reserves at 27.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Bolt Biotherapeutics Industry Peers by Asset Resilience Ratio
Compare Bolt Biotherapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Bolt Biotherapeutics (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Bolt Biotherapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.85% | $15.80 Million | $56.75 Million | -12.42pp |
| 2024-12-31 | 40.27% | $40.12 Million | $99.63 Million | -16.92pp |
| 2023-12-31 | 57.19% | $91.38 Million | $159.78 Million | -12.89pp |
| 2022-12-31 | 70.08% | $159.64 Million | $227.81 Million | +18.46pp |
| 2021-12-31 | 51.62% | $158.84 Million | $307.72 Million | +14.46pp |
| 2020-12-31 | 37.16% | $17.30 Million | $46.54 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $48.45 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $15.97 Million | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agon… Read more